Physician profile
Hannah Testa
NPI 1700650215
$8,010.01
in general payments reported to CMS, 2019-2025
17 companies · $5,135 in 2025
The $5,135 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $2,875 · 2025: $5,135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,940 · Consulting Fee: $1,800 · Education: $270.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,940.04 |
| Consulting Fee | $1,800.00 |
| Education | $269.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $3,622.90 | 2024-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $901.91 | 2024-2025 | |
| Abbvie INC. | $425.46 | 2024-2025 | |
| Galderma Laboratories, L.P. | $369.42 | 2024-2025 | Nemluvio, Aklief |
| Sun Pharmaceutical Industries INC. | $346.24 | 2024-2025 | |
| Ucb, INC. | $344.49 | 2024-2025 | Bimzelx |
| Janssen Scientific Affairs, LLC | $340.89 | 2024-2025 | Tremfya |
| Arcutis Biotherapeutics, INC. | $302.31 | 2025 | Zoryve |
| Genzyme Corporation | $281.80 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $247.09 | 2024-2025 | Dupixent |
| Leo Pharma INC. | $150.90 | 2024-2025 | Adbry, Anzupgo |
| Organon LLC | $138.20 | 2025 | Vtama, Nexplanon |
| Amgen INC. | $135.91 | 2025 | Otezla, Otezla |
| Novo Nordisk INC | $126.30 | 2024 | |
| Verrica Pharmaceuticals INC. | $111.90 | 2024 | Ycanth |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $110.58 | 2024 | Vtama |
| Lilly USA, LLC | $53.71 | 2025 | Ebglyss |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Testa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.